Editorial Policies

Focus and Scope

Journal of Drug Delivery and Therapeutics is a peer-reviewed journal dedicated to the publication of research papers, reviews, mini-reviews, Short communications and case studies.

This publication is aimed at a broad, interdisciplinary audience of academic and industrial researchers actively engaged in basic and applied laboratory practice, related to Pharmaceutical Science and Therapeutics.

The journal covers:

Medical Sciences (medicine, surgery, ophthalmology, gynecology and obstetrics, pediatrics, orthopedics, microbiology, pathology and laboratory medicine, medical education, medical ethics, community medicine and public health, anatomy, physiology, pharmacology).

Pharmaceutical Sciences (Biotechnology, Biochemistry, DRA, Phytomedicine /Ayurveda, Pharmaceutics, Drug Delivery, Pharmaceutical Chemistry, Pharmaceutical Analysis)



Section Policies


Checked Open Submissions Checked Indexed Checked Peer Reviewed


Checked Open Submissions Checked Indexed Checked Peer Reviewed

Mini Review

Checked Open Submissions Checked Indexed Checked Peer Reviewed

Short Communication

Checked Open Submissions Checked Indexed Checked Peer Reviewed

Case Studies

Checked Open Submissions Checked Indexed Checked Peer Reviewed


Unchecked Open Submissions Checked Indexed Checked Peer Reviewed

Letter to Editor

Checked Open Submissions Checked Indexed Checked Peer Reviewed

Book Review

Unchecked Open Submissions Unchecked Indexed Unchecked Peer Reviewed

Peer Review Process

All Submissions should conform to the Uniform Requirements for Manuscripts Submitted to Medical Journals by ICMJE.

This journal follows double-blind peer review system. All submissions will be reviewed by at least two independent reviewers. All manuscripts will be acknowledged upon presenting to the Journal office, provided that all stated requirements are met. All manuscript subjected to preliminary review by editorial team before sending it to the reviewers for review. Authors are encouraged to suggest names of two expert reviewers, but the selection of reviewer will depend on the decision of Editors. Review process depends on receiving reviewers comments and revision of manuscript by authors must adhere to the comments provided by reviewers. Authors have the right to communicate to the editor if they do not wish their manuscript to be reviewed by a particular reviewer because of potential conflicts of interest. No article is rejected unless negative comments are received from at least one reviewer.

Approximately 55 percent of submitted manuscripts are accepted for publication.

Authors should expect to hear the results of the manuscript peer review within 5 weeks from the date of submission. Authors receive the reviewers’ comments and are often asked to revise the manuscript in line with the reviewers’ and/or editor’s suggestions within 4 weeks. If the revised article is accepted for publication, the editor then determines the journal issue in which it will appear. Accepted articles will usually appear in the next issue of the journal.



Publication Frequency

Journal of Drug Delivery & therapeutics bimonthly journal (6 issue/year). We always publish every issue timely since starting of this journal. Issue schedule is 15-Jan, 15-March, 15-May, 15-July, 15-September and 15-November in every year for issue 1, 2, 3, 4, 5 and 6 respectively.



Open Access Policy

This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge.



This journal utilizes the LOCKSS system to create a distributed archiving system among participating libraries and permits those libraries to create permanent archives of the journal for purposes of preservation and restoration. More...

This Journal provides an OAI-PMH(Open Archives Initiatives Protocol for Metadata Harvesting) interface for metadata harvesting. We fully support and implement the OAI version 2.0, which comes in a standard XML format.


Publication Ethics and Malpractice Statement

Publication ethics and malpractice statement of this journal, adapted from and based on guidelines provided by Committee on publication ethics (COPE). (http://publicationethics.org) and International Committee for Medical Journal Editor (ICMJE) http://www.icmje.org/

Journal of Drug Delivery and Therapeutics is a peer-reviewed journal dedicated to the publication of research papers, reviews, mini-reviews, Short communications and case studies.

Section A: Author's Responsibilities

As part of the submission process, authors are required to check off their submission's compliance with all of the following items, and submissions may be returned to authors that do not adhere to these guidelines.

  1. The submission has not been previously published, nor is it before another journal for consideration (or an explanation has been provided in Comments to the Editor).
  2. The submission file is in Open Office, Microsoft Word, RTF, or WordPerfect document file format.
  3. Where available, URLs for the references have been provided.
  4. Manuscripts should be written as per instructions provided in Authors Guidelines section and accompanied by a covering letter stating the originality and significance of the submitted manuscripts.
  5. The text adheres to the stylistic and bibliographic requirements outlined in the Author Guidelines, which is found in About the Journal.
  6. Numbers of Authors: Authorship should be limited to those who have made a significant contribution to conception, design, execution or interpretation of the reported study.
  7. If at any point,  the author(s) discovers a  significant error in submitted manuscript,  then the error or inaccuracy must be reported to the editor.
  8. The authors should ensure that they have written entirely original works, and if the authors have used the work and/or words of others that this has been appropriately cited or quoted.
  9. The corresponding author should ensure that all appropriate co-authors and no inappropriate co-authors are included on the paper and that all co-authors have seen and approved the final version of the paper and have agreed to its submission for publication.
  10. Proper acknowledgment of the work of others must always be given. Authors should cite publications that have been influential in determining the nature of the reported work.
  11. If the work involves chemicals, procedures or equipment that have any unusual hazards inherent in their use, the author must clearly identify these in the manuscript.

Section B: Reviewers' responsibilities

  1. Reviewers should keep all information regarding papers confidential and treat them as privileged information.
  2. Reviews should be conducted objectively, with no personal criticism of the author.
  3. Reviewers should express their views clearly with supporting arguments.
  4. Reviewers should identify relevant published work that has not been cited by the authors.
  5. Reviewers should also call to the Editor in Chief's attention any substantial similarity or overlap between the manuscript under consideration and any other published paper of which they have personal knowledge.
  6. Reviewers should not review manuscripts in which they have conflicts of interest resulting from competitive, collaborative, or other relationships or connections with any of the authors, companies, or institutions connected to the papers.

Section C: Editorial Staff’s responsibilities

  1. The editor is responsible for deciding which of the articles submitted to the journal should be published.
  2. Unpublished materials disclosed in a submitted manuscript must not be used in an editor's own research without the express written consent of the author.
  3. An editor at any time evaluates manuscripts for their intellectual content without regard to race, gender, sexual orientation, religious belief, ethnic origin, citizenship, or political philosophy of the authors.
  4. The editor and any editorial staff must not disclose any information about a submitted manuscript to anyone other than the corresponding author, reviewers, potential reviewers, other editorial advisers, and the publisher, as appropriate.
  5. Disclosure and conflicts of interest:
    Unpublished materials disclosed in a submitted manuscript must not be used in an editor's own research without the express written consent of the author.

Section D: Publisher’s Responsibilities

Maintain Relationship

To maintain the relationship with editors and parties involved in the publication and should support the editorial decisions and should work in the way to achieve the publication goal set by the editor.

Maintain confidentiality

To maintain the confidentiality of author and his/her research work.

Maintain the policies

To promote and encourage policies regarding journals ethics, authorship, editorial independence, conflict of interest, research funding, review system and process.

Corrections, Retractions, Republication, and errors

To publish corrections, clarification, retractions whenever required. Publication should be done on the timely basis to achieve timeliness of publishing schedule of the journal.

Honest errors are a part of science and publishing and require publication of a correction when they are detected. So Correction, Retractions, Republication, and errors are handled as per standards prescribed by IJMJE

What to do if case of redundant (duplicate) publication

What to do if case of suspect plagiarism

What to do if case of fabricated data

If Changes in authorship

Corresponding author requests addition of extra author before publication
( http://publicationethics.org/files/u2/04A_Author_Add_Submitted.pdf )

Corresponding author requests removal of author before publication
( http://publicationethics.org/files/u2/04B_Author_Remove_Submitted.pdf )

Request for addition of extra author after publication
( http://publicationethics.org/files/u2/04C_Author_Add_Published.pdf )

Request for removal of author after publication
( http://publicationethics.org/files/u2/04D_Author_Remove_Published.pdf )

Suspected guest, ghost or gift authorship
( http://publicationethics.org/files/u2/04E_Author_Ghost_Guest_Gift.pdf )

Advice on how to spot authorship problems
( http://publicationethics.org/files/u2/04F_How_to_spot_author_problems.pdf )

What to do if a reviewer suspects case of undisclosed conflict of interest (CoI) in a submitted manuscript
( http://publicationethics.org/files/u2/05A_CoI_Submitted.pdf )

What to do if a reader suspects case of undisclosed conflict of interest (CoI) in a published article
( http://publicationethics.org/files/u2/05B_CoI_Published.pdf )

What to do if case an ethical problem with a submitted manuscript
( http://publicationethics.org/files/u2/06_Ethics_Submitted.pdf )

What to do if case of reviewer has appropriated an author’s idea or data
( http://publicationethics.org/files/u2/07_Reviewer_misconduct.pdf )

How COPE handles complaints against editors
( http://publicationethics.org/files/u7140/Flowchart%20Complaints%20revised%20Apr%2012.pdf )


Guide to Reviewers

Journal of Drug Delivery and Therapeutics team value reviewers’ recommendations and our systems are designed to make reviews easier for them to accept articles for review, complete their reviews and provide rapid feedback.

Confidentiality is very important in all aspects of the reviewing cycle; we expect the highest standards of professional behavior from all our reviewers. Author data must be kept securely until discarded by electronic shredding. Manuscript be written in high quality English and be justified. It is essential that all reviewers declare any conflicts of or completing interests.

Journal of Drug Delivery and Therapeutics considers the following article types: Research article, Review, Mini Review, Case study, Editorial, Letter to Editor, Short communication, Book Review.

Journal of Drug Delivery and Therapeutics reviewing system provided following separate sections for authors and editor in which reviewers will post comments after review has been completed

Recommendations to the editor:

These comments are confidential. Only the Editor-in-Chief and/or Executive Editor will have access to this. We recommend that the space to be used to report any serious concern about the study directly to the senior editors.

Recommendations to the authors:

This is the main peer-review reporting area. This section is visible for authors as well as for editor-in-Chief. Reviewer can leave their detailed comments in this section after review.

It will be very useful if the reviewer divided his/her review report into sub-sections (e.g. abstract, introduction…etc.) and commented on each of them independently.
It may help our authors if these questions are answered:

  1. Is the title of paper within the scope of the journal?
  2. Is the rationale for this work well stated?
  3. Are the objectives clearly stated?
  4. Are assumptions described and their reasonableness supported or rejected?
  5. Are limitations and uncertainties in the data and analyses given?
  6. Were alternative hypotheses and interpretations adequately considered?
  7. Are the results presented in an objective, unbiased fashion?
  8. Are the conclusions supported by the data?
  9. Is the writing clear, concise and precise?
  10. Are the results are original?
  11. Are the results are significant?
  12. Are the references citation pattern is perfect?
  13. Are the figures/illustrations/tables relevant?
  14. Are tables, figure captions/legends appropriate?


Comments on the statistics
This section can be used to comment on the statistical analysis of the study. The reviewer should highlight the fact that the manuscript may require review by a statistician, if appropriate.

Recommendation by reviewers

Accept (Accept as it is, no changes)

Revision required (author must respond comments provided and resubmit the revised manuscript within given period of time. Revised manuscript will be accepted or again will be sent to reviewer)

See comments (Author must respond the given comments. Editor will take the appropriate decision after receiving the revise article as per comments provided)

Decline (article has low standard as compare to scientific requirement of journal)

Editors-in-Chief will invite journal and/or external 'peer reviewers' by an automated time-lined email system. Reviewers will receive an email invitation to review a manuscript with the manuscript abstract. If a reviewer is able to complete the 'peer review', he/she may log in to the reviewers page to gain full access to the manuscript. If the reviewer is unable to review the manuscript they may use the decline link within the invitation email to decline the invitation allowing another reviewer to be selected in a timely manner.

Once an invitation is accepted, the reviewer will have access to the whole manuscript and any supplementary information. Reviewers must read the whole submission. Reviews may only be submitted on-line within our time lined 'peer review' system which is generally 4 weeks.


Policy statement – Human and Animal Rights

Any investigations involving humans and animals should be approved by the Institutional Review Board and Animal Care Committee, respectively, of the institution where the study took place. Journal of Drug Delivery and Therapeutics will not consider any studies involving humans or animals without the appropriate approval. If no formal ethics committee is available, the authors should indicate whether the procedures were compliant with the Helsinki Declaration as revised in 2008. Informed consent should be obtained, unless waived by the Institutional Review Board, from patients who participated in clinical investigations. Human subjects should not be identifiable, such that patients' names, initials, hospital numbers, dates of birth, or other protected healthcare information should not be disclosed. If experiments involve animals, the research should be based on national or institutional guidelines for animal care and use. Original articles submitted to  Journal of Drug Delivery and Therapeutics that address any investigation involving humans and animals should include a description about whether the study was conducted under an approval by the Institutional Review Board (with or without patient informed consent) and animal care committee, respectively, of the institution where the study was conducted.


Policy statement – Conflict of Interest

All Authors publishing in Journal of Drug Delivery and Therapeutics must declare all financial disclosures and conflicts of interest in the article file of manuscripts submitted for publication.

For more information on Conflict of Interest, see the guidelines from the ICMJE.


Policy statement – Informed Consent

All human studies submitted for publication in Journal of Drug Delivery and Therapeutics require informed consent and ethics committee approval. If waiver of consent was granted by the ethics committee in the case of retrospective studies not impacting on patient confidentiality or patient rights, this must be clearly stated in the cover letter and manuscript.


Screening for plagiarism

The journal staff has a policy of screening for plagiarism. All articles in this publication are original: the content (either in full or in part) in each article has not been knowingly republished without specific citation to the original release. Plagiarism checker is applied randomly to the majority of the papers submitted.



Article Processing Charges(APC) and Waiver Policy


Journal of Drug Delivery and Therapeutics is an Open Access journal. Publishing an article in this Journal requires Article Processing Charges that will be billed to the submitting author following the acceptance of an article for publication. Apart from these Article Process Charges, there are no submission charges, page charges, or color charges. The fees to be paid following the acceptance of an article are indicated below:

1500 Indian Rupees/article for Indian Authors

USD 40/article for Authors from Low-Income Countries.

USD 50/article for Authors from Low-Middle Income Countries.

USD 60/article for Authors from Upper-Middle-Income Countries

USD 90/article for Authors from High-Income Countries. (No other hidden charges)

Waiver Policy as per World Bank Country Classification

We provide a waiver of Article Processing Charges to authors based on country classification by World Bank

We can also waive 100% in some special condition depend on if there is no funding and author not able to charge any fees. In order to apply for a waiver, please request one before submitting your manuscript by sending an email to editor.jddt@gmail.com

You can find more details about the list of country as per classification of World Bank' below here;



Burkina FasoHaitiSierra Leone
BurundiKorea, Dem. People's Rep.Somalia
Central African RepublicLiberiaSouth Sudan
Congo, Dem. RepMaliUganda
Gambia, TheNiger



ArmeniaJordanSão Tomé and Principe
BangladeshKenyaSolomon Islands
BhutanKiribatiSri Lanka
Cabo VerdeKyrgyz RepublicSwaziland
CambodiaLao PDRSyrian Arab Republic
Congo, Rep.MauritaniaTimor-Leste
Côte d'IvoireMicronesia, Fed. Sts.Tunisia
Egypt, Arab Rep.MongoliaUzbekistan
El SalvadorMoroccoVanuatu
GhanaNicaraguaWest Bank and Gaza
GuatemalaNigeriaYemen, Rep.

Papua New Guinea



American SamoaGabonParaguay
BelarusIran, Islamic Rep.Russian Federation
Bosnia and HerzegovinaJamaicaSerbia
BotswanaKazakhstanSouth Africa
BrazilLebanonSt. Lucia
BulgariaLibyaSt. Vincent and the Grenadines
ChinaMacedonia, FYRSuriname
Costa RicaMaldivesTonga
CroatiaMarshall IslandsTurkey
Dominican RepublicMontenegroVenezuela, RB
Equatorial GuineaNamibia



Antigua and BarbudaGreenlandPortugal
ArubaGuamPuerto Rico
AustraliaHong Kong SAR, ChinaQatar
AustriaHungarySan Marino
Bahamas, TheIcelandSaudi Arabia
BarbadosIsle of ManSingapore
BelgiumIsraelSint Maarten (Dutch part)
BermudaItalySlovak Republic
British Virgin IslandsJapanSlovenia
Brunei DarussalamKorea, Rep.Spain
CanadaKuwaitSt. Kitts and Nevis
Cayman IslandsLatviaSt. Martin (French part)
Channel IslandsLiechtensteinSweden
CuraçaoLuxembourgTaiwan, China
CyprusMacao SAR, ChinaTrinidad and Tobago
Czech RepublicMaltaTurks and Caicos Islands
DenmarkMonacoUnited Arab Emirates
EstoniaNetherlandsUnited Kingdom
Faroe IslandsNew CaledoniaUnited States
FinlandNew ZealandUruguay
FranceNorthern Mariana IslandsVirgin Islands (U.S.)
French PolynesiaNorway

Waiver Application Process
  • Author(s) requesting for waiver must strongly demonstrate why their waiver applications should be granted.
  • Request for a waiver must be sent same day a manuscript is submitted to editor.jddt@gmail.com.
  • Waiver request should contain the following information
Manuscript ID and Title
Corresponding Author Affiliation and Country
List co-author(s) Affiliation(s) and Country
Reason for requesting a waiver for processing fees
  • We reserve the right to approve or reject a waiver application. Waiver decision will be communicated to the corresponding author within one week after the application is received.



this Journal carries an advertisement, which generates income, but journal not be dominated by advertisements, and advertising must not be allowed to influence editorial decisions.

Journal follows advertising policies as per ICMJE.

ISSN: 2250-1177  This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License.